orantinib has been researched along with Adenocarcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Bruns, CJ; Guba, M; Jauch, KW; Kleespies, A | 1 |
| Kohno, T; Konno, R; Machida, S; Mizuno, I; Ohwada, M; Saga, Y; Suzuki, M; Takayama, T; Takei, Y | 1 |
| Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q | 1 |
| Boschi, F; D'Onofrio, M; Faccioli, N; Marzola, P; Pozzi Mucelli, R; Sbarbati, A | 1 |
1 review(s) available for orantinib and Adenocarcinoma
| Article | Year |
|---|---|
Vascular endothelial growth factor in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A | 2004 |
2 trial(s) available for orantinib and Adenocarcinoma
| Article | Year |
|---|---|
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate | 2005 |
2 other study(ies) available for orantinib and Adenocarcinoma
| Article | Year |
|---|---|
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Topics: Adenocarcinoma; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Microcirculation; Neoplasms, Experimental; Organometallic Compounds; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Tamoxifen | 2007 |